376 related articles for article (PubMed ID: 22596228)
1. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
Décard BF; Haghikia A; Tönnes C; Thöne J; Lukas C; Chan A; Gold R
Mult Scler; 2013 Feb; 19(2):249-51. PubMed ID: 22596228
[TBL] [Abstract][Full Text] [Related]
2. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
Eisele P; Szabo K; Hornberger E; Griebe M; Hennerici MG; Kieseier BC; Gass A
J Neuroimaging; 2014; 24(4):425-8. PubMed ID: 23323645
[TBL] [Abstract][Full Text] [Related]
3. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
Maillart E; Louapre C; Lubetzki C; Papeix C
Mult Scler; 2014 Apr; 20(4):505-9. PubMed ID: 24367037
[TBL] [Abstract][Full Text] [Related]
4. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
6. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
Damasceno A; von Glehn F; Martinez AR; Longhini AL; Deus-Silva L; Brandão CO; Santos LM; Damasceno BP
Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
[No Abstract] [Full Text] [Related]
7. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
[TBL] [Abstract][Full Text] [Related]
8. JCV-negative natalizumab-associated progressive multifocal leukoencephalopathy: a clinico-radiological diagnosis.
Travasarou M; Marousi S; Papageorgiou E; Karageorgiou CE
Clin Neurol Neurosurg; 2013 Jun; 115(6):827-9. PubMed ID: 22920632
[No Abstract] [Full Text] [Related]
9. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients.
Dahlhaus S; Hoepner R; Chan A; Kleiter I; Adams O; Lukas C; Hellwig K; Gold R
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1068-74. PubMed ID: 23606731
[TBL] [Abstract][Full Text] [Related]
10. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
[TBL] [Abstract][Full Text] [Related]
11. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab (tysabri)-associated progressive multifocal leukoencephalopathy: insights from perfusion magnetic resonance imaging.
Elster MJ
J Comput Assist Tomogr; 2013; 37(5):694-7. PubMed ID: 24045242
[TBL] [Abstract][Full Text] [Related]
13. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
[TBL] [Abstract][Full Text] [Related]
14. Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
Hoepner R; Ahlbrecht J; Faissner S; Schneider R; Dahlhaus S; Adams O; Raab P; Lukas C; Chan A; Stangel M; Gold R
J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1177-8. PubMed ID: 24700881
[No Abstract] [Full Text] [Related]
15. Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy.
Taieb G; Renard D; Thouvenot E; Servillo G; Castelnovo G
J Neurol Sci; 2014 Nov; 346(1-2):364-5. PubMed ID: 25241939
[No Abstract] [Full Text] [Related]
16. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
Ziemssen T; Gass A; Wuerfel J; Bayas A; Tackenberg B; Limmroth V; Linker R; Mäurer M; Haas J; Stangel M; Meergans M; Harlin O; Hartung HP
BMC Neurol; 2016 Jul; 16():98. PubMed ID: 27405225
[TBL] [Abstract][Full Text] [Related]
17. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
Yousry TA; Pelletier D; Cadavid D; Gass A; Richert ND; Radue EW; Filippi M
Ann Neurol; 2012 Nov; 72(5):779-87. PubMed ID: 23280794
[TBL] [Abstract][Full Text] [Related]
18. The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas?
Phan-Ba R; Belachew S; Outteryck O; Moonen G; Sindic C; Vokaer M; Vermersch P
Neurology; 2012 Sep; 79(10):1067-9. PubMed ID: 22914844
[No Abstract] [Full Text] [Related]
19. Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: a case report.
Piola M; Di Palma F; Mascoli N; Binda S; Arnaboldi M; Rezzonico M
J Neurol Sci; 2014 May; 340(1-2):213-4. PubMed ID: 24642511
[TBL] [Abstract][Full Text] [Related]
20. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
Serana F; Chiarini M; Sottini A; Bertoli D; Giustini V; Tessitore MV; Caimi L; Capra R; Imberti L
J Neuroimmunol; 2014 Dec; 277(1-2):6-12. PubMed ID: 25468273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
